Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:37 PM
Ignite Modification Date:
2025-12-24 @ 4:37 PM
NCT ID:
NCT02426866
Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
* Aged 18 years or older on the index date
* Have at least one pharmacy claim for efavirenz or a drug in the comparison cohort during the period spanning January 1, 2007 through December 31,2013.
* Clinical Modification (ICD-9) diagnosis code for HIV infection including 042 (HIV disease), V08 (asymptomatic HIV infection status), 795.71 (nonspecific serologic evidence of HIV), and 079.53 (HIV, type 2) any time prior to the index claim.
* Have at least 6 months (180 days) of continuous enrollment prior to the index claim
Exclusion Criteria:
* Patients who have been dispensed any antiretroviral medications anytime before the index date including the 180-day baseline period
* Patients with evidence of a cardiovascular outcome of interest during the 180-day baseline period
Healthy Volunteers:
False
Minimum Age:
18 Years
Study:
NCT02426866
Study Brief:
Protocol Section:
NCT02426866